Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
Investigational New Drugs
|
December 2, 2015
A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors
Manik Amin, Susan E Minton, Patricia M LoRusso, et al.
Journal of Clinical Pharmacology
|
September 21, 2010
Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation
Diana M Brainard, Kelem Kassahun, Larissa A Wenning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 2, 2021
First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Lillian L Siu, Ding Wang, John Hilton, et al.
The Journal of Clinical Investigation
|
June 27, 2017
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers, Jared Lunceford, Michael Nebozhyn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Razvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, et al.
Nature Medicine
|
June 1, 2024
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial
Thomas Powles, Yen-Hwa Chang, Yoshiaki Yamamoto, et al.
The Lancet. Oncology
|
May 10, 2016
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro, Hyun Cheol Chung, Veena Shankaran, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2022
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
Robert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2012
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors
Ian Krop, Tim Demuth, Tina Guthrie, et al.
JAMA Oncology
|
December 21, 2018
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study
Manish A Shah, Takashi Kojima, Daniel Hochhauser, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
Investigational New Drugs
|
December 2, 2015
A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors
Manik Amin, Susan E Minton, Patricia M LoRusso, et al.
Journal of Clinical Pharmacology
|
September 21, 2010
Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation
Diana M Brainard, Kelem Kassahun, Larissa A Wenning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 2, 2021
First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Lillian L Siu, Ding Wang, John Hilton, et al.
The Journal of Clinical Investigation
|
June 27, 2017
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers, Jared Lunceford, Michael Nebozhyn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Razvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, et al.
Nature Medicine
|
June 1, 2024
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial
Thomas Powles, Yen-Hwa Chang, Yoshiaki Yamamoto, et al.
The Lancet. Oncology
|
May 10, 2016
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro, Hyun Cheol Chung, Veena Shankaran, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2022
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
Robert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2012
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors
Ian Krop, Tim Demuth, Tina Guthrie, et al.
JAMA Oncology
|
December 21, 2018
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study
Manish A Shah, Takashi Kojima, Daniel Hochhauser, et al.
Page
of 3